Ilka Haenssgen

Title: Innovator Spotlight: Ilka Haenssgen and Her Contributions to Protein Research

Introduction: Ilka Haenssgen is an accomplished inventor based in Halle/Saale, Germany. She has made significant strides in the field of protein research, particularly in the development of modified ubiquitin proteins with specific binding activities. Her innovative work demonstrates the potential to enhance medical treatments through advanced protein engineering.

Latest Patents: Ilka Haenssgen holds a notable patent for "Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin." This invention presents novel hetero-multimeric proteins derived from modified ubiquitin, which are capable of binding the extradomain B of fibronectin (ED-B) with high affinity. In addition, the patent outlines fusion proteins that incorporate the recombinant protein fused to a pharmaceutically and/or diagnostically active component, showcasing its applications in medical treatment methods.

Career Highlights: Ilka Haenssgen is affiliated with Scil Proteins GmbH, where she actively contributes to cutting-edge research in protein functionality and applications. Her expertise has been instrumental in advancing the company's mission to develop innovative solutions for the pharmaceutical and biotechnology industries.

Collaborations: Throughout her career, Ilka has worked alongside esteemed colleagues such as Arnd Steuernagel and Erik Fiedler. These collaborations have enriched her work and fostered a culture of innovation and teamwork at Scil Proteins GmbH.

Conclusion: Ilka Haenssgen's pioneering work in modifying ubiquitin proteins exemplifies her dedication to advancing scientific knowledge and improving medical treatments. Her contributions highlight the importance of innovation in the field of protein research, as well as the collaborative spirit that drives progress in this vital area of study.